Potential Combination Update - Poolbeg Pharma and HOOKIPA Pharma are in discussions regarding a potential combination, with significant shareholder Gilead Sciences indicating its intention to vote in favor of the deal if a formal offer is made [2][3] - Gilead owns 1,875,947 HOOKIPA common shares, representing 19.4% of HOOKIPA's existing issued share capital [3] Fundraise Details - HOOKIPA has amended the details of its planned Fundraise, now expecting to undertake a 100% primary private placement fundraise of approximately $30 million+, up from the previously stated $30 million [4] - Oppenheimer & Co Inc has been engaged as the placement agent for the private placement fundraise [5] Advisors and Contacts - Poolbeg has engaged Cavendish Capital Markets, Canaccord Genuity, Shore Capital, and J&E Davy as financial advisers and brokers [6][7][14][15] - HOOKIPA has engaged Moelis & Company as its financial adviser [8][16] - Contact details for key executives and investor relations teams at both companies are provided [6][7]
Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA